AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Axial Biotherapeutics to Participate in 5th Annual BMO Private Company Showcase

October 11, 2019 GMT

WALTHAM, Mass.--(BUSINESS WIRE)--Oct 11, 2019--

Axial Biotherapeutics, a biotechnology company dedicated to building a unique class of gut-targeted programs for neurodegenerative diseases and neurodevelopmental disorders, today announced that the company will present at the 5 th Annual BMO Private Company Showcase on Friday, October 18, 2019 at 9:40 AM ET.

About Axial Biotherapeutics

Axial Biotherapeutics is a clinical stage biopharmaceutical company pioneering novel science focused on the interaction between the brain and the gut to mitigate the causes and symptoms of CNS and other gut-derived diseases. The Company has built a pipeline of novel small-molecules and live biotherapeutics with lead programs to address the significant unmet patient needs associated with Parkinson’s Disease and Autism Spectrum Disorder.

View source version on businesswire.com:https://www.businesswire.com/news/home/20191011005018/en/

CONTACT: Investors:

Julie Seidel

Stern Investor Relations, Inc.

212-362-1200

julie.seidel@sternir.com

KEYWORD: UNITED STATES NORTH AMERICA MASSACHUSETTS

INDUSTRY KEYWORD: MENTAL HEALTH HEALTH CLINICAL TRIALS PHARMACEUTICAL BIOTECHNOLOGY

SOURCE: Axial Biotherapeutics

Copyright Business Wire 2019.

PUB: 10/11/2019 08:01 AM/DISC: 10/11/2019 08:01 AM

http://www.businesswire.com/news/home/20191011005018/en